Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical trials

February 25, 2019, Melbourne, Australia – Aravax, a clinical stage biotechnology company focused on developing the next generation of peanut allergy immunotherapy with advan...

February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy...